Featured Studies

The risk of heart disease among African Americans is still common despite a greater understanding of the disease and better approaches to managing it. Healthy cooking and eating patterns can help reduce the risk of heart disease. But things like access to grocery stores and knowledge of good nutrition can affect these healthy patterns. Researchers at The National Institutes of Health want to see if community-based programs can help.

A study at NIH is recruiting healthy African Americans and African-born individuals to better understand diabetes and heart disease risk in Black populations. If you are African American or African-born Black between the ages of 18 and 70 years.

Systemic lupus erythematosus (SLE) creates an imbalance in the innate immune system responsible for chronic inflammation. A study at NHLBI is looking into a Vitamin B supplement, nicotinamide riboside (NR), to see if it improves immune system function in people with SLE. People with SLE will be asked to take the supplement or placebo for 12 weeks. Healthy control subjects will be enrolled to compare baseline blood results but will not take the supplement.

Doctors at the National Institute on Deafness and Other Communication Disorders (NIDCD) are investigating the effectiveness of atorvastatin (a drug used to lower “bad“ cholesterol and fats such as LDL, and triglycerides, and raise “good“ cholesterol such as HDL, in the blood) at reducing the incidence of hearing loss in patients treated with cisplatin for head and neck cancer. (En español)

Researchers from the National Cancer Institute at the NIH Clinical Center are currently looking for patients who have HER2-expressing endometrial cancer. The purpose of the study is to test two investigational study drugs, a vaccine that targets HER2 (AdHER2DC) and a drug that is expected to improve immune cell function (N-803). These study drugs will be used with pembrolizumab and lenvatinib which are FDA approved to treat endometrial cancer.

Doctors at the National Institute on Deafness and Other Communication Disorders (NIDCD) are investigating the effectiveness of atorvastatin (a drug used to lower “bad“ cholesterol and fats such as LDL, and triglycerides, and raise “good“ cholesterol such as HDL, in the blood) at reducing the incidence of hearing loss in patients treated with cisplatin for head and neck cancer.